FDA-recognized Poly-L-Lactic Acid formula with 20-year medical legacy. Contains 365mg/vial of medical-grade PLLA microparticles (40-63μm diameter) suspended in sodium carboxymethylcellulose. Clinically validated to stimulate Type I collagen production with 82% patient satisfaction at 24-month follow-up (2022 multicenter study).

Biomimetic Technology:
PLLA microparticles (150mg) + osmotic stabilizers (mannitol 125mg) create controlled inflammatory response. Post-injection hydrolysis generates CO₂/H₂O while stimulating fibroblast activity. Collagen deposition peaks at 6-8 weeks, with cumulative improvement through 3-session protocol.

Clinical Notice: Individual collagen response varies (±18% from baseline). Optimal outcomes require proper injection depth (subdermal layer) and post-treatment massage. Manufacturer assumes no liability for off-label use or unlicensed administration.